Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Children's Hospital Medical Center, Cincinnati
In the first stage, drug levels will be obtained to establish appropriate dosing. In the second stage of the study the investigators will study the effects of using Maraviroc in these patients.
Age
5–40
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Ages 5 years and \</= 40 years
All diagnoses
Peripheral blood stem cells, marrow or cord blood
All conditioning regimens
Patient must be planned to receive a calcineurin inhibitor (cyclosporine or tacrolimus) together with steroid, methotrexate or mycophenolate mofetil as GVHD prophylaxis.
You may not be if
Documented anaphylaxis to Maraviroc
Ex vivo T-cell (type of white blood cell) depleted grafts
Abnormal Alanine Aminotransferase (ALT) (\>/=10X ULN) on day -3. (Assessed at study enrollment and confirmed again prior to the first dose of maraviroc.)
